Advertisement
Research Article

Rare Variants in APP, PSEN1 and PSEN2 Increase Risk for AD in Late-Onset Alzheimer's Disease Families

  • Carlos Cruchaga mail,

    cruchagc@psychiatry.wustl.edu (CC); goatea@psychiatry.wustl.edu (AMG)

    Affiliation: Department of Psychiatry and Hope Center Program on Protein Aggregation and Neurodegeneration, Washington University, St. Louis, Missouri, United States of America

    X
  • Sumitra Chakraverty,

    Affiliation: Department of Psychiatry and Hope Center Program on Protein Aggregation and Neurodegeneration, Washington University, St. Louis, Missouri, United States of America

    X
  • Kevin Mayo,

    Affiliation: Department of Psychiatry and Hope Center Program on Protein Aggregation and Neurodegeneration, Washington University, St. Louis, Missouri, United States of America

    X
  • Francesco L. M. Vallania,

    Affiliation: Department of Genetics, Washington University, St. Louis, Missouri, United States of America

    X
  • Robi D. Mitra,

    Affiliation: Department of Genetics, Washington University, St. Louis, Missouri, United States of America

    X
  • Kelley Faber,

    Affiliation: Department of Medical and Molecular Genetics, Indiana University, Indianapolis, United States of America

    X
  • Jennifer Williamson,

    Affiliation: Taub Institute for Research on Alzheimer's Disease and the Aging Brain, Columbia University College of Physicians and Surgeons, New York, New York, United States of America

    X
  • Tom Bird,

    Affiliation: VA Medical Center and Departments of Neurology and Medicine, University of Washington, Seattle, Washington, United States of America

    X
  • Ramon Diaz-Arrastia,

    Affiliation: Department of Neurology, University of Texas Southwestern Medical Center, Dallas, Texas, United States of America

    X
  • Tatiana M. Foroud,

    Affiliation: Department of Medical and Molecular Genetics, Indiana University, Indianapolis, United States of America

    X
  • Bradley F. Boeve,

    Affiliation: Department of Neurology, Mayo Clinic, Rochester, Minnesota, United States of America

    X
  • Neill R. Graff-Radford,

    Affiliation: Department of Neurology, Mayo Clinic, Jacksonville, Florida, United States of America

    X
  • Pamela St. Jean,

    Affiliation: Genetics, GlaxoSmithKline, Research Triangle Park, North Carolina, United States of America

    X
  • Michael Lawson,

    Affiliation: Genetics, GlaxoSmithKline, Research Triangle Park, North Carolina, United States of America

    X
  • Margaret G. Ehm,

    Affiliation: Genetics, GlaxoSmithKline, Research Triangle Park, North Carolina, United States of America

    X
  • Richard Mayeux,

    Affiliation: Taub Institute for Research on Alzheimer's Disease and the Aging Brain, Columbia University College of Physicians and Surgeons, New York, New York, United States of America

    X
  • Alison M. Goate mail,

    cruchagc@psychiatry.wustl.edu (CC); goatea@psychiatry.wustl.edu (AMG)

    Affiliations: Department of Psychiatry and Hope Center Program on Protein Aggregation and Neurodegeneration, Washington University, St. Louis, Missouri, United States of America, Department of Genetics, Washington University, St. Louis, Missouri, United States of America

    X
  • for the NIA-LOAD/NCRAD Family Study Consortium
  • Published: February 01, 2012
  • DOI: 10.1371/journal.pone.0031039

Reader Comments (1)

Post a new comment on this article